NEW YORK (PRWEB)
September 30, 2021
Citeline Connect, the all-in-one clinical trial recruitment platform developed by Informa Pharma Intelligence, has added Glooko to its patient recruitment collective, supported by the platform that brings together 75 vetted partners to simultaneously refer qualified patients to clinical trials. Glooko’s software platforms empower the management of diabetes and related conditions by collecting and unlocking the power of data, with access to over 35 billion data points globally, the largest in the world.
As the coronavirus pandemic has illustrated, diversity in clinical trials is increasingly important. Citeline Connect was chosen by two leading pharmaceutical companies to help quickly meet recruitment goals for diverse populations for COVID-19 vaccine trials. Diversity is particularly important for diabetes clinical trials; Hispanic individuals have higher levels of diabetes than the general population. According to the American Diabetes Association, Black Americans are 60% more likely to be diagnosed with diabetes than other groups. It is precisely these minorities who are underrepresented in clinical trials. Industry statistics show that while nearly 40% of Americans belong to an ethnic or racial minority, participants in clinical trials skew between 80% and 90% white.
Compounding the problem are ineffective pre-screening processes. Across disease states, 69% of patients fail to meet pre-screening criteria. According to one study of screen failure in diabetes clinical trials, renal inclusion criteria caused the most screen fails in Asians, whereas Blacks had the highest cardiovascular inclusion screen failure.
Citeline Connect features a robust pre-screening process. By partnering with Glooko — known for its remote patient monitoring solutions for diabetes and related chronic conditions such as obesity and hypertension — Citeline Connect will enhance pre-screening for these patients. Glooko’s technology supports over 200 devices, syncing with diabetes, fitness, biometric and other devices to capture real world data. It also integrates with the top EHR systems used in the industry.
Overall, for two consecutive years tracked by the Food and Drug Administration (FDA), the number of endocrinology, diabetes, and metabolism clinical trial participants declined considerably. In 2015, U.S. trials totaled 5,449, compared to 11,830 in the rest of the world. In 2016, the numbers plummeted to 665 in the U.S. and 4,063 elsewhere.
Citeline Connect, in conjunction with Glooko, is poised to reverse this trend by referring qualified diabetes patients to clinical trials. The Citeline Connect referral network is continually expanding to include organizations whose focus is on specific diseases and conditions. Other specialties include oncology, celiac and Crohn’s diseases, and psoriasis, as well as other rare diseases.
“At Citeline Connect, we are committed to helping clinical trial sponsors efficiently find — and recruit — the patients who specifically meet their inclusion and exclusion criteria,” said Mike Wenger, Vice President of Patient Engagement at Informa Pharma Intelligence. “While diabetes is a more common disease, this still can be like finding a needle in a haystack. That’s why we are expanding our patient recruitment collective with vetted partners such as Glooko that work like a magnet to attract those needles.”
“Glooko is very pleased to partner with Citeline Connect on this integration of our technologies,” said Russ Johannesson, CEO of Glooko. “At Glooko, we are proud to be the global leader in connected care for diabetes and adjacent chronic conditions like hypertension and obesity and are naturally leading the way for better remote data collection and management in connected clinical trials. Discovering new and novel therapeutics in pharma and medical devices is important in the quality of life and improved outcomes for patients with these conditions.”
For more information, visit https://www.citelineconnect.com or contact pharma@informa.com.
About Informa Pharma Intelligence
Citeline Connect, developed by Informa Pharma Intelligence, is the all-in-one clinical trial recruitment platform that accelerates trial enrollment via innovative technology and services. Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, powers a full suite of analysis products – including Datamonitor Healthcare™, Sitetrove™, Trialtrove™, Pharmaprojects™, Biomedtracker™, Scrip™, Pink Sheet™ and In Vivo™ – to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.
With more than 400 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information, visit pharmaintelligence.informa.com.
About Glooko
Glooko is transforming digital health by connecting people with diabetes and related conditions and their healthcare teams, enabling telehealth, clinical research, and improved collaboration. The company’s software platforms empower the management of diabetes and other chronic conditions by collecting and unlocking the power of data from blood-glucose meters, CGMs, insulin pumps, connected insulin pens, blood pressure cuffs, nutrition apps, connected weight scales and activity trackers – bringing insights together in one place. Data is easily uploaded – remotely via app or in-clinic, securely shared, and visualized in actionable charts and graphs. This creates a solid foundation enabling collaboration and confident treatment decisions. The platforms are compatible with over 95% of global diabetes devices along with health monitoring devices, giving people with diabetes and other chronic conditions and their care teams the freedom of choice. Over 3 million users have benefited from health data insights using Glooko’s solutions, which are trusted by world leaders in diabetes and chronic care, and used in 29 countries across 22 languages. Learn more at https://www.glooko.com.
Share article on social media or email: